Mirum Pharmaceuticals Q1 Earnings Call Highlights

Key Points

• Mirum reported Q1 net product sales of approximately $160 million (LIVMARLI: $84M U.S., $30M international) and raised full‑year 2026 net product sales guidance to $660–$680 million, driven primarily by U.S. PFIC demand.
• Clinical readouts advanced Mirum beyond pediatrics: VISTAS showed volixibat significantly improved pruritus in PSC and AZURE‑1 phase IIb supports brelovitug in hepatitis delta, prompting plans to expand into adult liver settings and scale the U.S. commercial team from ~20 to ~60 to reach >4,000 providers.
• Mirum licensed zilurgisertib for FOP from Incyte with a $60 million upfront, has an NDA accepted with priority review (PDUFA Sept. 26), could launch by year‑end if approved, and expects global peak sales of >$200 million.

Mirum Pharmaceuticals NASDAQ: MIRM reported first-quarter 2026 results and outlined plans to expand both its commercial footprint and clinical pipeline, highlighting continued demand for LIVMARLI and recent clinical updates in primary sclerosing cholangitis (PSC) and hepatitis delta. Management also detailed a newly announced licensing deal for an additional rare genetic disease program.

First-quarter sales growth and raised full-year guidance

President and Chief Operating Officer Peter Radovich said Mirum delivered “strong commercial execution,” reporting total net product sales of approximately $160 million for the quarter. Radovich said this included LIVMARLI net product sales of $84 million in the U.S. and $30 million internationally, while the company’s bile acid medicines contributed $46 million.

Chief Executive Officer Chris Peetz said LIVMARLI uptake “remains strong,” with performance in PFIC “continu[ing] to exceed expectations.” Based on demand and performance across the portfolio, Mirum raised its full-year 2026 net product sales guidance to $660 million to $680 million.

On the guidance increase, Peetz told analysts the primary driver was U.S. PFIC demand for LIVMARLI, adding that both pediatric and adult patients are initiating treatment, but “older adolescents and adults really is the major driver.” He also pointed to international performance, saying the company saw less of the historical Q1 seasonality and that PFIC is “starting to show up” in international sales.

Expanding the rare liver disease platform: PSC and hepatitis delta

Peetz said the company is entering “the next phase” of its rare liver disease business, citing recent clinical readouts in PSC and hepatitis delta that could move Mirum beyond its pediatric foundation into larger adult patient populations.

In PSC, Peetz said the VISTAS study of volixibat showed “a significant improvement in pruritus,” which he called “a major advance in PSC research” and said positions volixibat as a potential first approved medicine for PSC patients in the U.S. He added that Mirum expects late-breaking presentations for both VISTAS and AZURE at EASL later this month.

In hepatitis delta, Peetz said phase IIb results from AZURE-1 “further support the potential” for brelovitug in a setting where treatment options are “extremely limited.” In the Q&A, Peetz and Chief Medical Officer Joanne Quan addressed questions about efficacy measures and endpoint interpretation. Peetz said Mirum is focused on the composite endpoint of virologic response plus ALT normalization, noting those factors are “pointed to in the FDA guidance.” Quan added that Mirum has seen declines in viral measures “in everyone,” and said there was “certainly no evidence of lack of response or resistance,” while emphasizing that response can deepen with continued treatment and that upcoming phase III datasets will provide more clarity.

Commercial plans: expanding liver field teams into adult settings

Radovich said the PSC and hepatitis delta programs “build directly on the global commercialization platform” established for LIVMARLI, CTEXLI, and CHOLBAM, with plans to leverage existing infrastructure. He said Mirum intends to expand U.S. and international commercial teams starting later this year to reach adult liver settings, including gastroenterologists and other liver providers managing PSC, and broader care settings such as infectious disease and selected primary care providers to increase hepatitis delta diagnosis.

Radovich said Mirum’s current U.S. liver field commercial team of about 20 people reaches roughly 1,500 health care providers, mainly pediatric liver providers with some higher-volume adult providers. After a planned expansion to about 60 U.S. field commercial personnel, the company expects to reach more than 4,000 liver health care professionals. In response to a question on timing, Radovich said he expects the expanded team to be “fully on board” by early next year and active across pediatric and adult settings, with pipeline-related activity ramping upon potential FDA approvals.

Rare genetic disease push: licensing zilurgisertib for FOP

Mirum also announced the addition of zilurgisertib, a once-daily oral ALK2 inhibitor licensed from Incyte, for fibrodysplasia ossificans progressiva (FOP). Peetz described FOP as an ultra-rare, progressive disease in which patients develop bone in soft tissues, often resulting in wheelchair dependence by early adulthood and reduced life expectancy.

Radovich said FOP is “highly concentrated” in specialized tertiary centers, and Peetz characterized it as a strong fit with Mirum’s rare genetic disease commercial model. On patient numbers, Peetz cited approximately 300 identified patients in the U.S., sourced from patient advocacy group IFOPA, and noted the current NDA is for patients age 12 and older, which he said covers “the majority” of relevant patients.

Peetz said an NDA has been accepted with priority review and a PDUFA date of Sept. 26. If approved, Mirum expects to launch by year-end. He also said a European filing is upcoming and “could actually still” occur this quarter, with Incyte continuing to lead those activities for now. Peetz added that while the initial label is expected for age 12 and older, additional cohorts are underway that could support a lower age label over time.

Addressing competitive positioning, Peetz said zilurgisertib’s PROGRESS study data represent “a real step forward” in activity, tolerability, and safety versus currently available options, and he emphasized the convenience of an oral therapy. Management said it plans to discuss more details after the PROGRESS data are presented at a medical meeting; Peetz said Incyte wants the data presented first before broader public disclosure.

When asked about peak sales, Peetz said Mirum views “200 million-plus” as a global peak sales estimate over the brand’s lifecycle in FOP.

Quarterly financials, deal terms, and outlook

Chief Financial Officer Eric Bjerkholt said net product sales were $160 million in the quarter, up from $112 million in the year-ago period. He reported cash, cash equivalents, and investments of $421 million as of March 31, compared with $391 million at the start of the year. Bjerkholt said the cash contribution margin from the commercial business was in the “mid-50s%,” and cash flow from operations was about $2 million.

Bjerkholt said first-quarter financials were “significantly impacted” by one-time expenses tied to Mirum’s acquisition of Bluejay Therapeutics, which closed in January. He reported total net cash outflow related to the acquisition of $253 million, offset by net financing proceeds of about $260 million. Total operating expense for the quarter was $949 million, including $761 million associated with the Bluejay acquisition, R&D expense of $98 million, SG&A of $96 million, and cost of sales of $29 million.

On the Incyte licensing agreement, Bjerkholt said Mirum paid an upfront payment of $60 million and that Incyte is eligible for additional development and regulatory milestones, including $25 million upon U.S. FDA approval for FOP, as well as sales-based milestones and tiered royalties on worldwide net sales in the “mid to high single-digit percent range.” Peetz also said Mirum expects the program to be eligible for a rare pediatric disease priority review voucher, but under the agreement Incyte would retain that voucher. Peetz added that Incyte will continue leading the review process through approval, after which Mirum would take over sponsorship in the U.S.

Bjerkholt said the company expects R&D expense to step up in 2026 as Mirum invests in brelovitug ahead of an anticipated BLA submission next year, noting that first-quarter R&D included $21 million related to brelovitug development. On profitability, Bjerkholt said the path is “much more driven by brelovitug and volixibat,” and stated that profitability “will be pushed out probably till 2028 on the GAAP basis,” while Peetz reiterated the company expects to be operating cash flow positive next year.

About Mirum Pharmaceuticals NASDAQ: MIRM

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.